A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis

  • Christopher L. Bowlus*
  • , Michael R. Galambos
  • , Richard J. Aspinall
  • , Gideon M. Hirschfield
  • , David E.J. Jones
  • , Yvonne Dörffel
  • , Stuart C. Gordon
  • , Stephen A. Harrison
  • , Andreas E. Kremer
  • , Marlyn J. Mayo
  • , Paul J. Thuluvath
  • , Cynthia Levy
  • , Mark G. Swain
  • , Guy W. Neff
  • , David A. Sheridan
  • , Carmen M. Stanca
  • , Christoph P. Berg
  • , Aparna Goel
  • , Mitchell L. Shiffman
  • , John M. Vierling
  • Pol Boudes, Alexandra Steinberg, Yun Jung Choi, Charles A. McWherter
*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

19 Downloads (Pure)
Original languageEnglish
Number of pages0
JournalJournal of Hepatology
Volume0
Issue number0
Early online date30 Mar 2022
DOIs
Publication statusPublished - 30 Mar 2022

Cite this